Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal stem cell therapy.
10.23876/j.krcp.2017.36.2.200
- Author:
Jun Seop KIM
1
;
Jong Hak LEE
;
Owen KWON
;
Jang Hee CHO
;
Ji Young CHOI
;
Sun Hee PARK
;
Chan Duck KIM
;
Yong Jin KIM
;
Yong Lim KIM
Author Information
1. Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. ylkim@knu.ac.kr
- Publication Type:Case Report
- Keywords:
Autologous transplantation;
Chronic kidney disease;
Mesenchymal stem cells
- MeSH:
Acute Kidney Injury;
Adipose Tissue;
Biopsy;
Dialysis;
Fibrosis;
Humans;
Infusions, Intravenous;
Korea;
Mesenchymal Stromal Cells*;
Renal Dialysis;
Renal Insufficiency*;
Renal Insufficiency, Chronic;
Stem Cells;
Transplantation, Autologous
- From:Kidney Research and Clinical Practice
2017;36(2):200-204
- CountryRepublic of Korea
- Language:English
-
Abstract:
Administration of autologous mesenchymal stem cells (MSCs) has been shown to improve renal function and histological findings in acute kidney injury (AKI) models. However, its effects in chronic kidney disease (CKD) are unclear, particularly in the clinical setting. Here, we report our experience with a CKD patient who was treated by intravenous infusion of autologous MSCs derived from adipose tissue in an unknown clinic outside of Korea. The renal function of the patient had been stable for several years before MSC administration. One week after the autologous MSC infusion, the preexisting renal insufficiency was rapidly aggravated without any other evidence of AKI. Hemodialysis was started 3 months after MSC administration. Renal biopsy findings at dialysis showed severe interstitial fibrosis and inflammatory cell infiltration, with a few cells expressing CD34 and CD117, 2 surface markers of stem cells. This case highlights the potential nephrotoxicity of autologous MSC therapy in CKD patients.
